Table 1. NY-ESO-1 tissue analysis.

NY-ESO-1 analysis was performed on all archived paraffin-fixed tumor tissues submitted for screening. N/A, not applicable.

nIHC, n (% positive)*PCR, n (% positive)Concordance,
n (% positive)
>5%>30%>5%>30%
All28069 (25)44 (16)55 (20)43 (62)32 (73)
Melanoma5517 (31)11 (20)19 (35)16 (94)10 (91)
Colorectal4112 (29)7 (17)6 (15)4 (33)1 (14)
Sarcoma4116 (39)15 (37)18 (44)15 (94)14 (93)
Synovial149 (64)9 (64)9 (64)8 (89)8 (89)
Leiomyosarcoma60 (0)0 (0)0 (0)N/AN/A
Not specified/other217 (33)6 (29)9 (43)7 (100)6 (100)
Lung388 (21)7 (18)4 (11)4 (50)4 (57)
Ovarian235 (22)1 (4)3 (13)2 (40)1 (100)
Bladder/urothelial133 (23)1 (8)1 (8)1 (33)1 (100)
Breast131 (8)1 (8)1 (8)1 (100)1 (100)
Other567 (13)1 (2)3 (5)0 (0)0 (0)

*Results are shown for NY-ESO-1 expression either at ≥5% of cells with ≥1+ intensity (cutoff used for study eligibility) or at >30% of cells with ≥1+ intensity.

†Threshold for positive was determined on the basis of negative and positive control samples.

‡Concordance between PCR and IHC positivity was determined at each IHC cutoff.